FDA Lifts Clinical Hold on Arbutus AB-101 IND Application
Arbutus said it was notified by the FDA that the clinical hold on its investigational new drug application for AB-101, an oral PD-L1 inhibitor, has been lifted.
Story updates
11:35:10 AM UTC
SquawkNews
Arbutus said the FDA removed the clinical hold on its IND for AB-101, an oral PD-L1 inhibitor for chronic HBV, enabling additional U.S. clinical development. The company is evaluating next steps.Material DetailsContext by AI AnalystThis is an early-to-mid stage regulatory clearing event for AB-101…
WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation NASDAQ:ABUS (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the Company was notified by the U.S. Food and Drug Administration (“FDA”) that th…